Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano 9 - 10 aprile 2010 C. Giannattasio Prevalence of Cardiovascular Disease in Americans Age 20 and Older by Age and Sex NHANES III: 1988-94 Source: © American Heart Association 2004 Cumulative Incidence of CVD Adjusted for the Competing Risk of Death for Men and Women according to Aggregate Risk Factor (RF) Burden at 50 Years of Age Men Women 0.7 69% 0.6 50% 0.5 46% 0.4 36% 0.3 0.2 0.1 Adjusted cumulative incidence Adjusted cumulative incidence 0.7 ≥ 2 major RFs 1 major RF ≥ 1 Elevated RF ≥ 1 Not optimal RF All optimal RFs 0.6 0.5 50% 0.4 39% 0.3 27% 0.2 0.1 8% 5% 0 0 50 60 70 80 Attained age 12640 M 90 50 60 70 80 90 Attained age Lloyd-Jones DM et al., Circulation 2006; 113: 791 Distribuzione dei fattori di rischio in Italia in rapporto al sesso (dati Istituto Superiore di Sanità, anno 2003) CVD Mortality Trends for Males and Females (United States: 1979-2004) Deaths in thousands 550 500 450 400 79 85 95 Years Males 12576 M Females Rosamond W et al., Circulation 2007; 115: e69 Deaths by Cause, Women, Latest Available Year, EU Other cancer 12% Respiratory disease 8% Injuries and poisoning 4% Breast cancer 4% Lung cancer 2% Colo-rectal cancer 3% Stomach cancer 1% Other causes 20% Other CVD 17% Stroke 14% 6979 M CHD 15% European Cardiovascular Disease Statistics, 2000 Acute MI Mortality by Age and Sex 30 25 Men Women 20 Death During Hospitalization (%) 15 10 5 0 <50 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-89 Age Source: Adapted from Vaccarino N Engl J Med 1999; 341(4): 217-225 Prognosis After MI 38% of women die within first year Compared to 25% of men 35% of women will have second MI within 6 years Compared to 18% of men Source: Wenger Circulation 2004; 109:558-560 L’infarto nella donna giovane 10 Diagnosis of Coronary Artery Disease in Women • Chest pain is experienced by most women with CHD, but non-chest pain presentations are more common in women than men • Other Presenting Symptoms – Upper abdominal pain, fullness, burning sensation – Shortness of breath – Nausea – Neck, back, jaw pain • Associations – Precipitated by exertion – Precipitated by emotional distress Source: Charney Cardiovasc Risk 2002, 9:303-307, Goldberg Am Heart J 1998. 136:189-195 Value of the Exercise ECG in Women 80 70 77 70 68 61 60 50 Men Women 40 30 20 10 0 Sensitivity Source: Kwok Y, Am J Cardiol 1999. 83(5):660-666 Specificity Women Receive Less Interventions to Prevent and Treat Heart Disease • Less cholesterol screening • Less lipid-lowering therapies • Less use of heparin, beta-blockers and aspirin during myocardial infarction • Fewer referrals to cardiac rehabilitation Source: Chandra 1998, Nohria 1998, Scott 2004, O’Meara 2004, Hendrix 2005 Mortality in Recent Cohort Studies of Patients Hospitalized with Heart Failure according to LVEF 90 Reduced LVEF Preserved LVEF 80 70 % death 60 50 40 30 20 10 0 0 1 2 3 4 5 6 Follow-up (years) 11368 M Hogg et al., JACC 2004; 43: 317 Processes Underlying Diastolic Dysfunction Blood Vessels Hypertension Aging Atherosclerosis Diabetes Hypertrophy Fibrosis Altered elastin & collagen calcification Endothelial dysfunction Loss of compliance Myocardium Hypertrophy (LVH) Fibrosis Cellular dysfunction Ischemia Increased stiffness Impaired relaxation Diastolic Dysfunction Heart Failure with Preserved Systolic Function 9421 M 18 21 Coronary Risk Chart Non-smoker mg/dl150 200 mmol/l 4 5 250 6 7 Smoker 300 mg/dl150 200 8 mmol/l 4 5 250 6 7 Non-smoker 300 age 70 140 120 180 age 160 60 SBP (mmHg) 140 120 180 160 age 140 50 120 180 age 160 40 140 mg/dl150 200 8 180 160 WOMEN Risk of Coronary Heart Disease 120 mmol/l 4 5 250 6 7 Smoker 300 mg/dl 150 200 8 mmol/l 4 180 180 160 160 140 140 120 120 180 180 160 160 140 140 120 120 180 180 160 160 age 140 140 120 120 50 180 180 160 160 140 140 120 120 5 250 6 7 300 8 180 age 160 70 140 120 180 age 160 60 140 120 180 160 140 120 180 age 160 40 140 120 10 Year Risk Level 180 180 age 160 160 30 140 140 120 120 mmol/l 4 5 mg/dl150 200 6 7 250 8 300 Cholesterol 5334 M mmol/l 4 5 mg/dl150 200 6 7 250 8 300 Cholesterol 180 Very high High Moderate Mild Low over 40% 20% to 40% 10% to 20% 5% to 10% under 5% 180 age 160 160 30 140 140 120 120 mmol/l 4 5 mg/dl150 200 6 7 250 8 300 Cholesterol mmol/l 4 5 mg/dl150 200 6 7 250 8 300 Cholesterol SBP (mmHg) MEN Risk of Coronary Heart Disease Staessen JA, 1983 AM J Edipemiol Focus sulla sindrome metabolica in menopausa Age-Specific Prevalence of the Metabolic Syndrome among 8814 US Adults, NHANES III, 1988-1994 50 Men Prevalence (%) 40 Women 30 20 10 0 20-29 30-39 40-49 50-59 60-69 > 70 Age (years) 2328 G Ford S et al., JAMA 2002 Terapia dell’ipertensione nella donna --I benefici del trattamento antipertensivo sono simili nei due sessi. È tuttavia sconsigliato l’impiego di ACE-inibitori e sartani nelle donne durante il periodo fertile e la gestazione per i potenziali effetti teratogeni Contraccettivi orali La terapia con contraccettivi orali a basso contenuto di estrogeni si associa ad un incremento del rischio di ipertensione,ictus e infarto del miocardio…… Terapia ormonale sostitutiva Le informazioni disponibili suggeriscono che gli unici vantaggi della terapia ormonale sostitutiva sono rappresentati da una minor frequenza di fratture ossee e di neoplasie del colon, mentre è aumentato il rischio di eventi coronarici e tromboembolici, ictus… Linee Guida ESH/ESC 2007 Treatment (2) ….Che farmaco usare? Tutti i farmaci antiipertensivi attraversano la placenta Dati comparativi tra i diversi farmaci riguardanti sia l’efficacia sia la sicurezza fetale e materna sono ancora inadeguati ACE inibitori e ARB controindicati perché teratogeni: stopparli anche nelle donne fertili che stanno programmando una gravidanza! METILDOPA (simpaticolitico centrale). Aldomet os 250 mg x 2/die, max 3 g/die Sicuro per madre e feto, blando antiipertensivo. Effetti collaterali: stipsi, depressione, sonnolenza, secchezza fauci LABETALOLO* (alfa 1 bloccante e beta bloccante non selettivo) 100 mg x 2/die, max 2.4 g/die I beta bloccanti cardioselettivi Beta1 (atenololo) possono ridurre la crescita fetale e placentare. I beta bloccanti non selettivi (propranololo) possono interferire con il rilassamento miometriale (processo beta2 relato) Calcio antagonisti (Adalat* 30-90 mg/die max 120 mg/die) Sicuri per madre e feto, sebbene non esistano molti studi per Ca antagonisti non diidropiridinici (verapamil, diltiazem), ed amlodipina. Maggiori informazioni per nifedipina * Consigliati anche durante l’allattamento